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INTRODUCTION 
Patent law only protects practical works of arts and not ideas 
or concept. This has always been the basis of the second pa-
tentability requirement. Philosophically it is to separate basic 
research science from applied science, avoids protecting pre-
mature, unwarranted, frivolous or injurious invention. Pro-
cedurally inventor must demonstrate the specific function, 
practical benefits and how to use the invention. Otherwise 
he must conduct further research to perfect the invention un-
til the real utility, capabilities and parameters of the same are 
known finally. 
CHARACTERS OF BIOTECHNOLOGICAL INVENTION
Biotechnological invention has many facets with specific 
characters. Some might be unique to biotechnology alone. 
It is important to appreciate them in order to understand the 
required capabilities in satisfying the second patentability 
requirement. Biotechnology is a highly technical and tech-
nologically sophisticated invention since it revolves around 
alteration and manipulation of deoxyribonucleic acid (DNA) 
and genes between same or transborder species through 
genetic engineering techniques. The transgenic nature of 
biotechnology inherently makes it controversial on morality, 
ethics, social acceptance, safety, environmental and health 
grounds. Lots of genetic materials are used in R&D to dis-
cover and extract the desired molecules and subsequently 
ascertain, characterize and manipulate the molecules with 
hope of identifying their true use and function in series of 
technologically sophisticated procedures. Such undertaking 
may take a longer time and costly. The effort could be ham-
pered by the inherently complex, not fully understood or un-
predictable character of DNA, genes and cellular system. A 
hybrid between science based research and applied science, 
biotechnology blurs the demarcation line, making it hard to 
clearly identify biotechnology’s utilities beyond the academic 
realms. At times biotechnology tends to lean more towards 
research and expansion of knowledge. It might be hard to 
convince patent office that such invention has practical utility, 
since the same has traditionally interpreted patentable sub-
ject matter is only for applied technology inventions. 
CHARACTERS AND CAPABILITIES OF LOCAL BIOTECH-
NOLOGY PLAYERS 
Majority of Malaysian biotechnology players are private small 
or medium size family business enterprises with small work-
ing capital and consequently annual budget. Most were pre-
viously technology users, new to the industry, had little or no 
experience as technology producers and rely on protected 
foreign technology. Access to latest technology is largely 
through licensing. Some are keen in employing family mem-
bers with no technological background in biotechnology to 
head the R & D department or senior posts in the company. 
Only 6 % of biotechnology companies have the desired state 
of art R&D facilities but they lack qualified employees to fully 
utilize them. 45% of biotechnology companies do not have 
any R&D facilities at all. They partnered with public research 
institutes or universities in conducting the R&D instead. 
Shortages of experienced-knowledge workers like intellec-
tual property experts, researchers, biotechnologist, genetic 
engineers, or computer programmer are common problems. 
The academic qualification of experienced-knowledge is not 
so-highly qualified as those found in developed nations. This 
affects their confidence in understanding and mastering the 
technological skill to conduct R&D to potentially produce 
new products. 
UTILITY REQUIREMENT 
Article 27 of Agreement on Trade Related Issues of Intel-
lectual Property Rights (TRIPS) accepts industrial applicabil-
ity and useful as second patentability requirement. Mem-
bers can choose the preferred term. TRIPS deems them as 
synonymous. Malaysia chose industrial applicability. The 
choice of term is important and far more complicated than 
mere preference of terms. The two may not necessarily the 
same. Each reflects a different meaning and standard. TRIPS 
phrased the utility requirement as the same as patent laws of 
developed nations. TRIPS impliedly expects members to use 
the same standard as developed nations in interpreting and 
applying the same. Certain inventions are patentable in one 
jurisdictions but not the other.  It could influent the future of 
an industry and rate of technological progression locally. In 
furtherance Article 27. 2 of TRIPS permit patent office to re-
ject a perfectly patentable invention from patent protection 
on ethics, safety, morality or environmental grounds. 
USEFUL
Only the United States of America and the Philippines are 
using useful as their utility requirement. Legally they have de-
fined the term broadly. The invention must be capable of use 
per se, thus easier to satisfy. It focuses on the “usefulness” of 
the invention, by looking at the practical function and capa-
bilities of the claim invention. The intended use of invention 
must not injure or harm the general public. Three key ele-
ments must be present in proving utility for biotechnological 
invention.  The invention must in its current form (i) has practi-
cal use, (ii) able to solve specific problem (iii) with real world 
value, beneficial to the society, not frivolous or injurious. For 
example if biotechnologist claims gene probe as the utility 
of his DNA sequence, he must disclose the targeted DNA 
specifically. 
INDUSTRIAL APPLICABILITY 
By definition, an invention is of “industrial applicability” 
when it can be made or used in any kind of industry including 
agriculture. The test is whether the invention can be used 
and made on industrial basis rather than what can the inven-
tion make or which industry could use it. In satisfying the util-
ity requirement, biotechnologist must disclose the specific, 
credible and beyond speculation the use and function of his 
invention through evidences. For example, it is insufficient for 
biotechnologist to claim his DNA sequence produces protein 
on industrial basis. He must show the specific function and 
benefits of the protein on potentially profitable basis. Oth-
erwise his assertion remains speculative, not containing any 
technical information thus non-patentable. 
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NARROWER CONCEPT
Generally both systems have the same the standard and bur-
den of prove in satisfying the utility requirement. Both expect 
biotechnological invention to have specific function, with 
practical real world use that benefits the public. Claims like a 
process is capable of (i) producing a biotechnological com-
pound or a product in the form of DNA and gene sequence 
or (ii) inherently capable of doing something inside living 
organisms as originally intended by nature are too general 
and unacceptable in both systems. Without specifying the 
ultimate function, a rDNA plasmid for example is none other 
than a strand of circular DNA. It is not until the molecule is 
inserted into a host cell that the DNA becomes operative and 
useful in replication and synthesizing the encoded protein. 
At closer look, the term industrial applicability comparatively 
has narrower concept and scope than useful. It is still insuf-
ficient to prove the biotechnological invention has specific 
function, practical use in real world and non injurious. Bio-
technologist must go one extra step in proving his invention 
has potential in generating profits commercially.  
Learning from the experiences of United States of America 
and European Union, the choice term shall render certain 
biotechnological inventions ineligible for patent protection. 
It naturally excludes biotechnological invention used for me-
dicinal purposes in surgery, diagnostic, or therapeutic treat-
ment. Undoubtedly these methods of treatment are useful 
thus patentable under “useful” jurisdictions but not industrial 
applicability jurisdictions. Understandingly such policy is to 
protect the medical professions and encourage them to of-
fer the best medical treatment to all. Otherwise hospitals or 
doctors have to pay licensing fees before laying their hands 
on the technology or liable for legal suit. 
TOO HIGH FOR LOCAL BIOTECHNOLOGY PLAYERS 
Currently the standard bar of industrial application is too high 
for invention from any field of technology to meet. The bar 
has been heightened further for biotechnology. On top of 
that, there are the safety and morality barriers to overcome. 
Due to biotechnological invention’s unique characteristics 
and weakness of local biotechnology players, the task of sat-
isfying the utility and safety requirements is easier said than 
done. The local players lack the necessary expertise, capac-
ity or technological capabilities and infrastructure. Even bio-
technologists from developed nations largely complained of 
their disabilities in proving the specific utility of invention in 
every case. Often the biotechnological inventions are with-
out known immediate use or useful for research only. With-
out indentifying the invention’s true capabilities, some of the 
empirical research based information might be speculative. 
Patent office is unlikely to see the logic of awarding such in-
vention with patent protection. Likewise when it is hard for 
the biotechnologist to specifically predict the usefulness or 
actual function of his invention, it shall be twice harder con-
templating its industrial applicability. 
SAFETY OR MORALITY REQUIREMENT 
Positively the safety and morality requirements protect the 
public from any hidden risks probably caused by biotechno-
logical inventions or treated as guinea pigs in a vast biotech-
nology experiment by unscrupulous few. Biotechnologist 
shall continue to face insurmountable battle against patent 
office, courts and public in proving the morality or safety of 
his invention. Whether the benefits out-weigh the risks so 
much so our morality accedes to patenting it would always 
be questioned. This is where the uncertainty starts. The con-
cept or degree of safety, morality and immorality has no fix 
answers. It changes with time, people and places, even with-
in a single country at a single time.  People naturally have a 
second thought.  The adopted standards adopted may differ 
from one society to the next. As such the patentability of bio-
technology invention would always dependable upon “sense 
of righteous” of the granting country leading to divergence 
of thoughts and results amongst worldwide communities. 
SLOW DOWN OF TECHNOLOGICAL PROGRESSION  
Patent law system demands certainty about the practical 
function, benefits and use- industrial application as well as 
the safety of biotechnological invention before patent pro-
tection is awarded. Biotechnologist may have to delay and 
continue conducting further research. If rich and large bio-
technology companies in developed nations constantly com-
plaining of the financial burden of finding and ascertaining 
them, the local biotechnology players would likely face the 
same problems twice harder. Their willpower, capabilities and 
resources would be stretch to the limit in pursuing the safety 
requirement too due to lack of technological capacity, capa-
bility and infrastructure. They have to consider and include 
the safety and morality analysis, which comprise of complete 
scientific data and information analyzing the impacts of in-
vention to society when planning their future or applying for 
patent. Again it mandated research activities and investiga-
tions. 
The high standard of utility requirements would delay local 
players from applying for patent protection and consequent-
ly hamper the dissemination of protected information to 
technology users. Most local players are heavily dependent 
on protected foreign technology, accessible provided they 
could afford the high price. As such the technology transfer 
would decrease and Malaysia as a whole would face a more 
acute problem of technological flow and adoption of tech-
nology than before. The biotechnology industry would take 
longer time to fully blossom.
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